Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarient launches KRAS colorectal cancer testing service in US

This article was originally published in Clinica

Executive Summary

Clarient has launched its KRAS genetic test for colorectal cancer. The services lab performs all testing at its site in Aliso Viejo, California so mainly caters for the US market, but also receives international samples "on a routine basis". Mutations in KRAS are associated with a poor response in patients treated with the EGFR inhibitors Vectibix, developed by Amgen, and Merck KGaA's Erbitux. Around 40-45% patients harbour the mutations, meaning the KRAS protein, which is downstream of the EGFR receptor, is always "turned on" regardless of whether EGFR is inhibited. Manchester, UK-based DxS also markets a KRAS test, TheraScreen K-RAS, which is CE marked for sale in Europe and was recently launched in Australia. However, DxS's test is not yet cleared by the US FDA.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041885

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel